VERAXA Biotech (NASDAQ: VRXA) announced the advancement of its bispecific antibody-drug conjugate (“bsADC”) program, VXA-222, after reaching a key technical milestone in its collaboration with OmniAb (NASDAQ: OABI). The company said OmniAb has successfully completed its discovery work, allowing the program to move into its next phase. VXA-222 is designed to target two tumor antigens with a single molecule using an “AND-gate” approach intended to improve precision in treating solid tumors.
Under the collaboration launched in May 2025, OmniAb provided antibody discovery technologies, including its OmniClic(TM) platform, while VERAXA is applying its proprietary linker technology and conjugation expertise to develop and validate the lead bsADC candidate. VERAXA holds exclusive rights to develop and commercialize products arising from the collaboration, with OmniAb entitled to a share of specified revenue generated from resulting products.
Questions around this news
What changed in VERAXA’s VXA-222 program?
The announcement says OmniAb has finished its antibody-discovery work for VXA-222, allowing the collaboration to proceed to another phase. VERAXA is now using its linker technology and conjugation expertise to develop and validate a lead bispecific ADC candidate. The release does not describe specific next-stage activities or a development timeline.
How does an AND-gate approach work in a bispecific ADC?
An AND-gate approach is designed to make a treatment act when two target conditions are present together, rather than responding to either one alone. In a bispecific ADC, one molecule can recognize two different antigens. The intended effect is greater selectivity, though actual performance depends on the particular design and testing.
What are the parties’ roles and rights in the collaboration?
OmniAb contributed antibody-discovery technology, including its OmniClic platform. VERAXA is responsible for applying linker technology and conjugation capabilities to advance and assess the lead candidate. The release says VERAXA has exclusive development and commercialization rights for products resulting from the work, while OmniAb is eligible for a portion of specified revenue from those products.
What is a bispecific antibody-drug conjugate?
An antibody-drug conjugate links an antibody to a drug payload so the antibody can bind a target and help deliver the payload. A bispecific version is designed to bind two different targets. Researchers develop these molecules to combine target recognition with delivery of a therapeutic agent; their effects depend on the molecule and clinical evidence.
To view the full press release, visit https://ibn.fm/qMRuJ
About VERAXA Biotech AG
At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
In brief
VERAXA Biotech says its VXA-222 bispecific antibody-drug conjugate program has reached a technical milestone, with OmniAb completing its discovery work under their collaboration. The program will now move to its next phase. VXA-222 is designed to recognize two tumor antigens through a single molecule, using an “AND-gate” strategy intended to improve targeting precision in solid tumors. The companies began working together in May 2025. OmniAb contributed antibody discovery technologies, including its OmniClic platform, while VERAXA is using its linker technology and conjugation capabilities to develop and assess a lead candidate. VERAXA holds exclusive development and commercialization rights to products resulting from the collaboration; OmniAb is eligible to receive a share of specified revenue from those products.
Key takeaways
- OmniAb completed discovery work for VERAXA’s VXA-222 bsADC program, the company says.
- The program is moving into its next phase following the technical milestone.
- VXA-222 is designed to target two tumor antigens with one molecule through an AND-gate approach.
- VERAXA holds exclusive rights to develop and commercialize products from the collaboration.
SEC filings
Earlier from VERAXA Biotech AG
- VERAXA Biotech (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany
- VERAXA Biotech (NASDAQ: VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform
- VERAXA Biotech (NASDAQ: VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development
- VERAXA Biotech (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership
- VERAXA Biotech (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy
